ResearcherVirginia Mason Medical CenterNo recent work listed
William Scott Helton
Matched on ORCID iD 0000-0002-5618-9426; OpenAlex author ID A5008245566. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper
Papers 6
- Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival. Last author DOI 10.1634/theoncologist.2019-0878↗
- Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.hpb.2018.03.014↗
- Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival? Co-author DOI 10.1245/s10434-018-6334-8↗
- Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. Co-author DOI 10.1245/s10434-016-5716-z↗
- Using Experience-Based Design to Improve the Care Experience for Patients With Pancreatic Cancer. Co-author DOI 10.1200/jop.2016.011213↗
- Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1067/j.cpsurg.2015.07.003↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Adnan A. Alseidi · 5 shared papers, 2015–2020 · strength 0.39
- Paper Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Pre… DOI 10.1634/theoncologist.2019-0878↗
- Paper Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma. DOI 10.1067/j.cpsurg.2015.07.003↗
- Paper Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenoca… DOI 10.1016/j.hpb.2018.03.014↗
- Flavio G. Rocha · 5 shared papers, 2015–2020 · strength 0.39
- Paper Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Pre… DOI 10.1634/theoncologist.2019-0878↗
- Paper Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma. DOI 10.1067/j.cpsurg.2015.07.003↗
- Paper Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenoca… DOI 10.1016/j.hpb.2018.03.014↗
- Vincent J. Picozzi · 5 shared papers, 2016–2020 · strength 0.39
- Paper Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Pre… DOI 10.1634/theoncologist.2019-0878↗
- Paper Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenoca… DOI 10.1016/j.hpb.2018.03.014↗
- Paper Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improve… DOI 10.1245/s10434-018-6334-8↗
- Richard A. Kozarek MD · 3 shared papers, 2017–2018 · strength 0.21
- Paper Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenoca… DOI 10.1016/j.hpb.2018.03.014↗
- Paper Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improve… DOI 10.1245/s10434-018-6334-8↗
- Paper Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Mu… DOI 10.1245/s10434-016-5716-z↗
- Stephen Y. Oh · 2 shared papers, 2017–2018 · strength 0.14
- Paper Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenoca… DOI 10.1016/j.hpb.2018.03.014↗
- Paper Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Mu… DOI 10.1245/s10434-016-5716-z↗
- John Bart Rose · 1 shared paper, 2020 · strength 0.11
- Farzad Alemi · 1 shared paper, 2015 · strength 0.07
- Zaheer S. Kanji · 1 shared paper, 2018 · strength 0.07
- Jesse Clanton · 1 shared paper, 2018 · strength 0.07
- Ann Hagensen · 1 shared paper, 2016 · strength 0.07
- C. Craig Blackmore · 1 shared paper, 2016 · strength 0.07
- L. William Traverso · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.